Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Erasca, Inc.ERAS · Entity 3796 | Chief Medical Officer | February 01, 2023 | February 03, 2023 |
| Revolution Medicines, Inc.RVMD · Entity 606 | Chief Medical Officer | March 17, 2026 | March 19, 2026 |
| TCGX Acquisition Corp.TCGX · Entity 6504 | Director | August 04, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Erasca, Inc.
Report date February 01, 2023 · Filed February 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 315,812 |
Reported balance
After 2023-02-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-02-01 · Other · Acquired 1,748 · Balance 315,812 F1: Includes 1,748 shares acquired under the Erasca, Inc. Employee Stock Purchase Plan (the ESPP) on June 15, 2022 and 2 shares acquired under the ESPP on December 15, 2022. |
| Common StockSEC Table I · non-derivative | Direct | 315,812 |
Reported balance
After 2023-02-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-02-01 · Other · Acquired 2 · Balance 315,812 F1: Includes 1,748 shares acquired under the Erasca, Inc. Employee Stock Purchase Plan (the ESPP) on June 15, 2022 and 2 shares acquired under the ESPP on December 15, 2022. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2033-01-31 | Direct | 560,000 |
Reported balance
After 2023-02-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-02-01 · Grant · Acquired 560,000 · Balance 560,000 F2: 1/48th of the shares subject to the option vest monthly following February 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,748 shares acquired under the Erasca, Inc. Employee Stock Purchase Plan (the ESPP) on June 15, 2022 and 2 shares acquired under the ESPP on December 15, 2022.
F2: 1/48th of the shares subject to the option vest monthly following February 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
Revolution Medicines, Inc.
Report date March 17, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 101,366 |
Reported balance
After 2026-03-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-17 · Sale · Disposed 2,073 · Balance 101,366 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after March 15, 2025. F2: Includes 62,050 RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after March 15, 2025.
F2: Includes 62,050 RSUs.
TCGX Acquisition Corp.
Report date August 04, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-04 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
2seventy bio, Inc.
Report date May 13, 2025 · Filed May 15, 2025
Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-05-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-13 · Disposition to issuer · Disposed 17,583 · Balance 15,267 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Row 2 · 2025-05-13 · Other · Disposed 15,267 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2025-05-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-13 · Disposition to issuer · Disposed 24,100 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.
F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2026 Filed Mar 19, 2026 22:57 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,073 | $99.48 | $206,222.87 |
DisclosureSEC source: 0001610717-26-000132 · form4.xml · nonDerivative · entry 1 Wei Lin · CIK 0001872772 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,366 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after March 15, 2025. F2 · balance_after: Includes 62,050 RSUs. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $102.02 | $0.00 |
DisclosureSEC source: 0001610717-26-000084 · form4.xml · derivative · entry 2 Wei Lin · CIK 0001872772 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2036-02-28 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 15,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000084 · form4.xml · nonDerivative · entry 1 Wei Lin · CIK 0001872772 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,439 F1 · balance_after: Includes 68,000 restricted stock units. Read SEC document |
| September 16, 2025 Filed Sep 18, 2025 20:39 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,160 | $45.82 | $98,981.78 |
DisclosureSEC source: 0001610717-25-000351 · form4.xml · nonDerivative · entry 1 Wei Lin · CIK 0001872772 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,339 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after March 15, 2025. F2 · balance_after: Includes 58,850 restricted stock units. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,173 | $39.83 | $86,550.59 |
DisclosureSEC source: 0001610717-25-000237 · form4.xml · nonDerivative · entry 1 Wei Lin · CIK 0001872772 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,499 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after March 15, 2025. F2 · price: This transaction was executed in multiple trades in prices ranging from $39.6017 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 1,021 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025. F4 · balance_after: Includes 64,800 RSUs. Read SEC document |
| May 13, 2025 Filed May 15, 2025 16:34 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | Disposition to issuerStock Options (Right to buy) · Derivative | 24,100 | Not disclosed Strike: $3.93 | Not disclosed |
DisclosureSEC source: 0001562180-25-003883 · primarydocument.xml · derivative · entry 3 Wei Lin · CIK 0001872772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,100 shares Expires not disclosed F4 · kind: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. F4 · price: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. Read SEC document |
| May 13, 2025 Filed May 15, 2025 16:34 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | OtherCommon Stock | 15,267 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-25-003883 · primarydocument.xml · nonDerivative · entry 2 Wei Lin · CIK 0001872772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. Read SEC document |
| May 13, 2025 Filed May 15, 2025 16:34 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | Disposition to issuerCommon Stock | 17,583 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-25-003883 · primarydocument.xml · nonDerivative · entry 1 Wei Lin · CIK 0001872772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,267 F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F2 · price: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 00:01 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 72,800 | $0.00 Strike: $40.74 | $0.00 |
DisclosureSEC source: 0001610717-25-000052 · form4.xml · derivative · entry 2 Wei Lin · CIK 0001872772 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,800 Underlying: Common Stock · 72,800 shares Expires 2035-02-28 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 00:01 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 20,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000052 · form4.xml · nonDerivative · entry 1 Wei Lin · CIK 0001872772 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,651 F1 · balance_after: Includes 70,750 restricted stock units. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 5,589 | $37.39 | $208,954.27 |
DisclosureSEC source: 0001610717-24-000347 · form4.xml · nonDerivative · entry 1 Wei Lin · CIK 0001872772 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,851 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $37.3867 to $37.3871, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 2,040 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2024. F4 · balance_after: Includes 59,250 RSUs. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 18:53 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Options (Right to buy) · Derivative | 24,100 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0001562180-24-005009 · primarydocument.xml · derivative · entry 2 Wei Lin · CIK 0001872772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,100 Underlying: Common Stock · 24,100 shares Expires 2034-06-10 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 10, 2025 or the date of the next annual meeting of stockholders of 2seventy bio, Inc. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 18:53 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 12,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005009 · primarydocument.xml · nonDerivative · entry 1 Wei Lin · CIK 0001872772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,850 F1 · security: These restricted stock units vest 100% on the earlier of June 10, 2025 or the date of the next annual meeting of stockholders of 2seventy bio, Inc. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 17:00 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (right to buy) · Derivative | 8,450 | $0.00 Strike: $11.81 | $0.00 |
DisclosureSEC source: 0001562180-23-005218 · primarydocument.xml · derivative · entry 2 Wei Lin · CIK 0001872772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,450 Underlying: Common Stock · 8,450 shares Expires 2033-06-13 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 13, 2024 or the date of the next annual meeting of stockholders of 2seventy bio, Inc. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 17:00 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 4,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005218 · primarydocument.xml · nonDerivative · entry 1 Wei Lin · CIK 0001872772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,800 F1 · security: These restricted stock units vest 100% on the earlier of June 13, 2024 or the date of the next annual meeting of stockholders of 2seventy bio, Inc. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:48 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (Right to buy) · Derivative | 33,400 | $0.00 Strike: $10.91 | $0.00 |
DisclosureSEC source: 0001562180-23-002688 · primarydocument.xml · derivative · entry 2 Wei Lin · CIK 0001872772 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,400 Underlying: Common Stock · 33,400 shares Expires 2033-03-07 F2 · derivative.exercise_date: This stock option vests ratably over three years in annual installments with the first installment vesting on March 7, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:48 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 16,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002688 · primarydocument.xml · nonDerivative · entry 1 Wei Lin · CIK 0001872772 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,600 F1 · security: This restricted stock unit award vests ratably over three years in annual installments with the first installment vesting on March 7, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 13:53 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (right to buy) · Derivative | 560,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006480 · doc4.xml · derivative · entry 3 Wei Lin · CIK 0001872772 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,000 Underlying: Common Stock · 560,000 shares Expires 2033-01-31 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following February 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 13:53 UTC | Erasca, Inc. ERAS · Entity 3796 | OtherCommon Stock | 2 | $3.89 | $7.79 |
DisclosureSEC source: 0001209191-23-006480 · doc4.xml · nonDerivative · entry 2 Wei Lin · CIK 0001872772 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,812 F1 · balance_after: Includes 1,748 shares acquired under the Erasca, Inc. Employee Stock Purchase Plan (the ESPP) on June 15, 2022 and 2 shares acquired under the ESPP on December 15, 2022. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 13:53 UTC | Erasca, Inc. ERAS · Entity 3796 | OtherCommon Stock | 1,748 | $4.10 | $7,161.56 |
DisclosureSEC source: 0001209191-23-006480 · doc4.xml · nonDerivative · entry 1 Wei Lin · CIK 0001872772 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,812 F1 · balance_after: Includes 1,748 shares acquired under the Erasca, Inc. Employee Stock Purchase Plan (the ESPP) on June 15, 2022 and 2 shares acquired under the ESPP on December 15, 2022. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:54 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (Right to Buy) · Derivative | 272,100 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0001209191-22-007065 · doc4.xml · derivative · entry 2 Wei Lin · CIK 0001872772 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,100 Underlying: Common Stock · 272,100 shares Expires 2032-01-31 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following February 2, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:54 UTC | Erasca, Inc. ERAS · Entity 3796 | OtherCommon Stock | 1,562 | $11.60 | $18,123.11 |
DisclosureSEC source: 0001209191-22-007065 · doc4.xml · nonDerivative · entry 1 Wei Lin · CIK 0001872772 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,062 F1 · balance_after: Includes 1,562 shares acquired under the Erasca, Inc. employee stock purchase plan on December 15, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.